Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA's Patrick Frey Joins List Of Agency Leadership Departures

Executive Summary

Office of New Drug's chief of staff will become Amgen's director of global regulatory policy and R&D.

You may also be interested in...



Leader Of US FDA's EU Mutual Recognition Effort Departs For Industry

Dara Corrigan will become Fresenius-Kabi’s VP for global affairs and policy.

US FDA Generic Drug Office Director Uhl Announces Retirement

Uhl, who shepherded OGD into the user fee era, will retire in February.

CDER Safety Overhaul Planned As Review Process Modernization Continues

US FDA's Woodcock tells the Pink Sheet that goals include eliminating duplication through creation of one safety review process.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS123689

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel